Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Yuling Han,Xiaohua Duan,Liuliu Yang,Benjamin E Nilsson-Payant,Pengfei Wang,Fuyu Duan,Xuming Tang,Tomer M Yaron,Tuo Zhang,Skyler Uhl,Yaron Bram,Chanel Richardson,Jiajun Zhu,Zeping Zhao,David Redmond,Sean Houghton,Duc-Huy T Nguyen,Dong Xu,Xing Wang,Jose Jessurun,Alain Borczuk,Yaoxing Huang,Jared L Johnson,Yuru Liu,Jenny Xiang,Hui Wang,Lewis C Cantley,Benjamin R tenOever,David D Ho,Fong Cheng Pan,Todd Evans,Huanhuan Joyce Chen,Robert E Schwartz,Shuibing Chen
DOI: https://doi.org/10.1038/s41586-020-2901-9
IF: 64.8
Nature
Abstract:There is an urgent need to create novel models using human disease-relevant cells to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) biology and to facilitate drug screening. Here, as SARS-CoV-2 primarily infects the respiratory tract, we developed a lung organoid model using human pluripotent stem cells (hPSC-LOs). The hPSC-LOs (particularly alveolar type-II-like cells) are permissive to SARS-CoV-2 infection, and showed robust induction of chemokines following SARS-CoV-2 infection, similar to what is seen in patients with COVID-19. Nearly 25% of these patients also have gastrointestinal manifestations, which are associated with worse COVID-19 outcomes1. We therefore also generated complementary hPSC-derived colonic organoids (hPSC-COs) to explore the response of colonic cells to SARS-CoV-2 infection. We found that multiple colonic cell types, especially enterocytes, express ACE2 and are permissive to SARS-CoV-2 infection. Using hPSC-LOs, we performed a high-throughput screen of drugs approved by the FDA (US Food and Drug Administration) and identified entry inhibitors of SARS-CoV-2, including imatinib, mycophenolic acid and quinacrine dihydrochloride. Treatment at physiologically relevant levels of these drugs significantly inhibited SARS-CoV-2 infection of both hPSC-LOs and hPSC-COs. Together, these data demonstrate that hPSC-LOs and hPSC-COs infected by SARS-CoV-2 can serve as disease models to study SARS-CoV-2 infection and provide a valuable resource for drug screening to identify candidate COVID-19 therapeutics.